Scarica l'app Stockscreener
26.30
1.54%
0.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.90
Aprire:
$25.89
Volume 24 ore:
51.91M
Relative Volume:
1.31
Capitalizzazione di mercato:
$149.04B
Reddito:
$63.63B
Utile/perdita netta:
$8.03B
Rapporto P/E:
18.65
EPS:
1.41
Flusso di cassa netto:
$8.23B
1 W Prestazione:
+3.02%
1M Prestazione:
-1.28%
6M Prestazione:
-9.40%
1 anno Prestazione:
-4.95%
Intervallo 1D:
$25.84
$26.57
Intervallo di 1 settimana:
$25.42
$26.57
Portata 52W:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.30 | 149.04B | 63.63B | 8.03B | 8.23B | 1.41 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market - News & Insights
Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez - CGTLive™
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes - Yahoo Finance
Pfizer shelves haemophilia gene therapy Beqvez amid low demand - Yahoo Finance
Pfizer: Investors Won't Stick Around Forever (NYSE:PFE) - Seeking Alpha
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair - BioPharma Dive
Pfizer stops selling hemophilia gene therapy, citing weak demand - BioPharma Dive
An awkward moment for Pfizer’s Bourla in Washington - STAT
Topical Drug Delivery Market Booming Innovations & Forecast 2032 with Johnson & Johnson, Pfizer Inc., GSK plc, - EIN News
Is Pfizer Inc. (PFE) the Best Non-Tech Stock to Buy Now for Long Term? - Insider Monkey
Capital Advisory Group Advisory Services LLC Makes New $292,000 Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
Bradley Foster & Sargent Inc. CT Purchases 139,215 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Health Rounds: Swabs as good as unpleasant speculum exam for detecting cancer-causing HPV - Marketscreener.com
Pfizer Inc. (NYSE:PFE) is WP Advisors LLC's 5th Largest Position - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Kentucky Retirement Systems Insurance Trust Fund - MarketBeat
Compass Capital Corp MA ADV Buys Shares of 49,457 Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters
ING Groep NV Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Ieq Capital LLC Purchases 40,117 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Bryn Mawr Capital Management LLC - MarketBeat
#Pfizer has announced a strategic marketing and supply agreement with Mylan Pharmaceuticals. The deal aims to bolster distribution and sales of its two well-known brands, Ativan and Pacitane, in India. #Pharmaceuticals - linkedin
Sanctuary Advisors LLC Cuts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Ataxia Market Future Business Opportunities 2025-2032 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics - openPR
Principal Financial Group Inc. Has $169.90 Million Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Trading Up 0%Still a Buy? - MarketBeat
Pfizer says it will end global development of hemophilia gene therapy Beqvez - TradingView
Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports -February 20, 2025 at 02:58 pm EST - Marketscreener.com
Pfizer halts work on hemophilia gene therapy - Nikkei Asia
Pfizer (NYSE:PFE) Shares Up 0.1%Here's What Happened - MarketBeat
Pfizer's Big Game Ad Wins LinkedIn Member Poll - Pfizer
What's Driving the Market Sentiment Around Pfizer? - Benzinga
U.S. Diabetic Neuropathy Market to Witness Stunning Growth with Eli Lilly & Company, Johnson & Johnson - EIN News
Boston Financial Mangement LLC Increases Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
14,772 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Advyzon Investment Management LLC - MarketBeat
First Bank & Trust Has $1.76 Million Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Davidson Investment Advisors Sells 100,344 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Handelsbanken Fonder AB Has $64.14 Million Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Private Wealth Partners LLC Raises Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Cumberland Partners Ltd Acquires Shares of 76,600 Pfizer Inc. (NYSE:PFE) - MarketBeat
Private Advisor Group LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Global Retirement Partners LLC Sells 24,744 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Vasopressin Market Is Booming Worldwide 2025-2032 | Par - openPR
Callahan Advisors LLC Purchases 69,155 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE) - TradingView
Trump to meet pharma leaders as they seek drug policy changes - Reuters
Pfizer (NYSE:PFE) Stock Price Down 0.6%Here's Why - MarketBeat
Pfizer (NYSE:PFE) Trading Up 0.9%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Up 0.1% on Insider Buying Activity - MarketBeat
TigerOak Management L.L.C. Purchases New Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.07%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):